Latest News and Press Releases

WESTPORT, Conn., May 14, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through...

WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers...

WESTPORT, Conn., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase...

WESTPORT, Conn., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase...

Intratumoral injections of INT230-6 were well tolerated with no drug-related serious adverse events or dose-limiting toxicity in Phase 1/2 clinical studyPreclinical research demonstrates drug...

Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors WESTPORT, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc.,...

Intratumoral injections of INT230-6 were well tolerated with no drug-related serious adverse events or dose-limiting toxicityIncreases in circulating CD8 and CD4 T-cells and evidence of abscopal...

Posters at European Society for Medical Oncology (ESMO) 2018 Congress and Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting to highlight safety of intratumoral INT230-6 in patients with...

Westport, CT, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced...